Table 1.
Various alginate-based drug delivery vehicles used in cancer therapy
| Description of Carrier | Type | Overcomes multi-drug resistance | Drug | Specify | Ref. |
|---|---|---|---|---|---|
| Chitosan-alginate polyelectrolyte multilayer capsule filled with bovine serum albumin gel (BSA-gel-capsule | Microcapsule | Local chemotherapy against drug-resistant (the treatment of drug-resistant breast cancer) | DOX | drug-resistant breast cancer (MCF-7 and MCF-7/ADR) | [92] |
| lectin-conjugated chitosan–Ca–Alginate | Microparticles | Deliver the drug molecules to colon region, and improve the efficacy in targeted anticancer colon drug therapy | 5-FU | Colon cancer (Caco-2) | [93] |
| Alginate-g-Poly(N-isopropylacrylamide) (alginate-g-PNIPAAm) | Injectable Hydrogel | Sustained release and effective delivery of anti-cancer drugs, overcoming the multidrug resistance in cancer treatment | DOX | prostate cancer (AT3B-1) | [94] |
| Alginate- Cyclodextrin | Nanogel | Enhance chemotherapeutic efficacy by pressure-controlled drug release | 5-FU | Colon cancer (HT-29) | [95] |
| Magnetic Alginate/Chitosan | Nanoparticles | Sustained release profiles, enhanced uptake efficiency, strong cytotoxicityto cancer cells, potential for targeted drug | Cur |
Human breast cancer (MDA-MB-231) |
[96] |
| Folate conjugated hyaluronic acid coated alginate | Nanogels | Antitumor and apoptosis efficacy on colon cancer therapy | OXA | Colorectal cancer (HT29) | [97] |
| Alginate-keratin composite | Nanogels | Better anti-tumor effect and lower side effects | DOX | Breast cancer (4T1 and B16) | [98] |
| Alginate nanogel platform | Nanogels | Inhibit tumor growth, reduce the adverse side effects, improve the quality of life of cancer patients. | Cisplatin/ Gold | Breast cancer (MCF-7) | [99] |
| Hybrid alginate/liposomes hydrogels | Liposome | Enhance chemotherapeutic efficacy by controlled drug release in oral cavity | DOX | Human tongue carcinoma (CAL-27) | [100] |
| Alginate-PAMAM (G5) hybrid nanogel | Dendrimer | Sustained release, targeted and sufficient tumor an accumulation, increased efficacy and decreased toxicity | EPI | Human breast cancer (MCF-7) | [101] |
| Dual crosslinked methacrylated alginate (Alg-MA | Sub-microspheres | Increase the efficacy of cell internalization and bioactivity of DOX-loaded Alg-MA, decreased in systemic toxicity of free drug | DOX | Human lung epithelial carcinoma cells (A549s) | [102] |